Infectious Disease Diagnostics Market

Infectious Disease Diagnostics Market by Product and Solution (Consumables, System, Software and Services), Technology (Immunodiagnostics, PCR, INAAT), Disease (HIV, HAIS, Influenza), End User (Hospital, Reference Lab, Research) - Global Forecast to 2027

Report ID: MRHC - 104274
Pages: 200
Jul-2020
Formats*: PDF
Category: Healthcare
Delivery: 2 to 4 Hours

COVID-19

This report provides pre & post COVID-19 market estimates.

Download sample here

The infectious disease diagnostics market is expected to grow at a CAGR of 6.9% from 2020 to 2027 to reach at $42.85 billion by 2027. The epidemiological burden of infectious diseases like severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), Ebola, chikungunya, avian flu, swine flu, and Zika has opened door for their early diagnosis & prevention. Similarly, current outbreak of COVID-19 pandemic has tremendously increased the demand for various POC diagnostic kits for early diagnosis and control the spread of coronavirus. Further, the growing awareness for early detection using specific diagnostic tests, growth in funding for research on infectious disease diagnostics, and shift in focus from centralized laboratories to decentralized point-of-care testing services are expected to propel the growth of the global infectious disease diagnostics market. However, unfavorable and inadequate reimbursement scenario is expected to hamper the growth of the infectious disease diagnostics market.

Infectious Disease Diagnostics Market

Click Here: To Get Your Free Sample Report Now

Impact of COVID-19 on Infectious Disease Diagnostics Market

The rising burden of infectious diseases and hospital acquired infections across the globe has increased the demand for infectious disease diagnostics products. Recent outbreak of the coronavirus disease (COVID-19) which has emerged since November 2019 in Wuhan, China has created destruction in several countries across the world. According to the WHO, as of 28^th April 2020, there were 3,073,603 confirmed cases, 2,11,768 confirmed deaths which has increased to 4,962,707 confirmed cases and 3,26,459 deaths worldwide as of 22^nd May 2020. In this global pandemic, although many dedicated healthcare professionals work tirelessly on the frontlines to fight against this crisis, it’s equally important to minimize the spread of disease by early diagnosis. Since its outbreak in November 2019, the disease has spread to many countries around the globe with the World Health Organization declaring it a public health emergency.

Testing is one of the greatest tools in understanding and managing the coronavirus pandemic. In response to the growing COVID-19 pandemic and shortages of laboratory-based molecular testing capacity and reagents, multiple diagnostic test manufacturers have developed and begun selling rapid and easy-to-use devices to facilitate testing outside of laboratory settings. These simple test kits are based either on detection of proteins from the COVID-19 virus in respiratory samples (e.g. sputum, throat swab) or detection, in blood or serum, of human antibodies generated in response to infection. Organizations around the world, including the Forum and its partners, are coming together and innovating to minimize the impact on public health and to limit disruptions to economies and supply chains. Some of the key initiatives undertaken by the manufacturers and organizations are as follows:

European governments have pledged over €7 billion in initial funding, as a part of a global effort to respond to the COVID-19 pandemic.
Partner of the World Economic Forum, Novo Nordisk Foundation, has taken an innovative approach since the beginning of the coronavirus pandemic to invest millions into research and development that will prepare Denmark for future viral epidemics. The Novo Nordisk Foundation has awarded a grant to TestCenter Danmark to carry out up to 3 million tests.
Global technology leader, Cisco Systems, is committing $225 million to help fight the COVID-19 pandemic.
Infosys, Strategic Partner of the Forum, has dedicated $13.6 million (INR 100 crore) in funding for hospital capacity treatment, ventilators, testing kits, and protective gear for frontline health workers to mitigate the impacts of COVID-19 across India.
Mylab Discovery Solutions (India), molecular diagnostics company, received commercial licence from the Central Drugs Standard Control Organisation (CDSCO) for its PathoDetect COVID-19 Qualitative PCR kit. The government is sourcing the Covid-19 kits from Germany to facilitate tests for diagnosing people infected with coronavirus across India. The recent validation to Mylab and German’s Altona diagnostics helps towards ramping up Covid-19 testing capacity and reducing the supply shortage of kits.
European Institute of Innovation & Technology (EIT) Health has announced funds of almost $7.69 million (7 million euros) in the fight against COVID-19, which will be dedicated to 15 health innovation projects across Europe. The projects will focus on immediate and impactful solutions for better tools in navigating the pandemic. e. the diagnostic testing.
Similarly, some of the key players operating in this market such as Abbott Laboratories (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), DiaSorin S.p.A. (Italy), Thermo Fisher Scientific Inc. (U.S.), Accurate Diagnostic Labs (U.S.), and Mylab Discovery Solutions (India) have also developed various diagnostic kits for early detection of COVID-19 in March & April 2020

Shift in focus from centralized laboratories to decentralized point-of-care services to propel the growth of the infectious disease diagnostics market

Molecular diagnostics has been done in centralized laboratories since many years, however, its few drawbacks like delay in results, high cost of tests, less accuracy, and late disease diagnosis have led to continuous shift in decentralizing clinical laboratory testing for infectious disease diagnosis. Point-of-care (POC) testing is majorly performed for the diagnosis purpose at or near the site where a patient initially encounters the health care system. POC tests have the potential to improve the patient management of infectious diseases. POC tests for various infectious diseases such as Chlamydia, gonorrhea, and influenza, among others, helps in providing early diagnosis and treatment. POC testing in the decentralized set up help the patient and the physicians to monitor the infectious diseases and improve the clinical workflow. In addition, improvement in the information technology contributed significantly in the process of decentralization of clinical laboratory testing.

Thus, the shift towards point of care testing is expected to accelerate the growth of the global infectious disease diagnostics market.

Key Findings in the Global Infectious Disease Diagnostics Market Study:

Immunodiagnostics segment to dominate the infectious disease diagnostics market in 2020

Based on technology, the immunodiagnostics segment is estimated to dominate the overall infectious disease diagnostics market in 2020. The dominance of this segment is mainly attributed to factors such as the Increasing use of immunoassays in infectious disease testing, development of novel tests, rising trend of automation, increasing awareness about health and fitness, and reduced complications associated with the instruments.

Based on products & solution, consumables segment to grow at the fastest CAGR during the forecast period

Based on products and services, the consumables segment is estimated to grow with the fastest CAGR during the forecast period, which is mainly attributed to the factors such as increasing prevalence of infectious diseases, rising awareness among the population to identify the diseases, and increasing use of kits and reagents to identify the organism causing various diseases in lesser time and cost. Further, the outbreak of coronavirus (COVID-19) disease since November 2019 is further expected to accelerate the growth of this segment owing to the national emergency declared and requirement of various kits and assays for early disease detection.

Hepatitis diseases to hold the largest share of the infectious disease diagnostics market in 2020

Based on diseases type, the hepatitis diseases segment is estimated to hold the largest share of the overall infectious disease diagnostics market in 2020. Increasing number of blood transfusions and donations, increasing prevalence of hepatitis B & C infections, rising susceptibility of the geriatric population, growing awareness among the population, and benefits offered by point of care instruments & kits are expected to propel the growth of this segment.

Asia Pacific: The fastest-growing market

At regional level, infectious disease diagnostics market is expected to be dominated by North America in 2020, while, Asia Pacific region is expected to grow at the fastest CAGR during the forecast period. The factors driving the growth of Asia Pacific infectious disease diagnostics market are rapid urbanization, increasing investments by healthcare providers towards infrastructure improvement, need to manage growing burden of infectious diseases, and government efforts to improve accessibility of diagnostic services to enhance the prevention by developing products or platforms required for the diagnosis of infectious diseases.

Key Players

The report includes competitive landscape based on extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the past 5 years (2016-2020). The key players profiled in the global infectious disease diagnosis market are Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux S.A. (France), Thermo Fisher Scientific (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), DiaSorin S.p.A. (Italy), Meridian Bioscience Inc. (U.S.), and Quidel Corporation (U.S.).

Scope of the Report:

Infectious Disease Diagnostics Market by Product & Solution

Consumables
Instruments
Software & Services

Infectious Disease Diagnostics Market by Technology

Immunodiagnostics
Clinical Microbiology
Polymerase Chain Reaction
Isothermal Nucleic Acid Amplification Technology
DNA Sequencing and Next-Generation Sequencing (NGS)
DNA Microarray Technology
Other technologies
(Other Technologies comprises of microscopy, hybridization, and loop-mediated isothermal amplification)

Infectious Disease Diagnostics Market by Disease Type

Hepatitis
Human Immunodeficiency Virus (HIV)
Hospital-Acquired Infections (HAIS)
Human Papillomavirus (HPV)
Tuberculosis (TB)
Influenza
Other Diseases
(Other diseases comprise of measles, smallpox, mumps, typhoid fever, malaria, meningitis, Ebola virus disease, Lyme disease, coronavirus disease, and whooping cough)

Infectious Disease Diagnostics Market by End User

Hospital/Clinical Laboratories
Reference Laboratories
Academics/Research Institutes
Other End Users
(Other end-users comprise of physician offices, nursing facilities, and home healthcare agencies)

Infectious Disease Diagnostics Market by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe (RoE)
Asia-Pacific (APAC)
- Japan
- China
- India
- Rest of APAC (RoAPAC)
Latin America
Middle East & Africa

Key questions answered in the report-

What is the revenue generated from infectious disease diagnostics products and services across the globe? At what rate their demand expected to grow for the next 5-7 years?

The global infectious disease diagnosis market is projected to reach $42.85 billion by 2027, at a CAGR of 6.9% during the forecast period of 2020-2027

Which technology segment showcases high growth opportunities for the infectious disease diagnostics market players?

The polymerase chain reaction (PCR) segment is expected to register the highest growth during the forecast period. PCR is a diagnostic test designed to confirm clinical disease, infection, or diagnose the cause of death in humans. This technique helps to detect the pathogen itself by amplifying very small traces of DNA and RNA of the pathogens, which are then detected in the assay. Continuous technological advancements in PCR technologies, its ability to detect infections in the latent phase, and less amount of template material requirement for the overall assay are the factors driving the growth of this segment.

Which end user segment of the market is projected to create more traction in the global infectious disease diagnostics market?

The reference laboratories segment is estimated to dominate the infectious disease diagnosis market in 2020 and is projected to register the fastest CAGR during the forecast period, mainly due to large number of samples received by reference laboratories for testing, and well-equipped and high throughput facilities to ensure quick turnaround of tests.

What are the key factors driving the growth of the infectious disease diagnostics market? What are the major opportunities for existing market players and new entrants in the market?

Rising prevalence of acute & chronic diseases; outbreaks of infectious diseases, such as COVID-19 and Ebola; growing awareness about early disease diagnosis; increasing number of hospitals and diagnostic laboratories; rising funds for research activities on infectious disease diagnostics; and shift in focus from centralized laboratories to decentralized point-of-care testing services are some of the major factors driving the growth of the market. In addition, the growing awareness about personalized medicine, advances in genomics and proteomics, current outbreak of COVID-19 pandemic, and growth opportunities in emerging markets provide significant growth opportunities for vendors across the globe.

How is the competitive rivalry and nature of infectious disease diagnostics market?

The global infectious disease diagnostics market is fragmented in nature and the key players, namely, Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and F. Hoffmann-La Roche Ltd. (Switzerland) are majorly driving the innovation trends in the market with their strategic developments.

Who are the prominent players in the global infectious disease diagnostics market?

Abbott Laboratories (U.S.), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), bioMÃ©rieux S.A. (France), Thermo Fisher Scientific (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (U.S.), DiaSorin S.p.A. (Italy), Meridian Bioscience Inc. (U.S.), and Quidel Corporation (U.S.) are some of the prominent players operating in the market.

Which regions/countries are expected offer significant growth opportunities for the vendors operating in infectious disease diagnostics market?

The emerging economies like China, India, Brazil, and Mexico based in Asia and Latin America are projected to offer significant growth opportunities for the vendors in this market with rising geriatric population, rapid rise in the prevalence of infectious diseases, growth in per capita income, increasing investments in the healthcare sector, growing number of hospitals and diagnostic laboratories, and sudden outbreak of COVID-19.

Download Sample

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for The Study
2.5. Limitations for The Study

3. Executive Summary

4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. Increasing Prevalence of Infectious Diseases
4.2.2. Growing Awareness of Early Disease Diagnosis
4.2.3. Impact of COVID-19
4.2.4. Rising Funds for Infectious Disease Diagnostics Research Activities
4.2.5. Shift in Focus from Centralized Laboratories to POC Testing Services
4.3. Restraints
4.3.1. Unfavorable and Inadequate Reimbursement Scenario
4.4. Opportunities
4.4.1. Advances in Genomics and Proteomics
4.4.2. Growing Awareness About Personalized Medicine
4.4.3. Emerging Economies
4.5. Challenges
4.5.1. Lack of Awareness of Specific Symptoms and Diagnosis of Emerging Infections

5. Global Infectious Disease Diagnostics Market, by Product & Service
5.1. Introduction
5.2. Consumables
5.3. Instruments
5.4. Software & Services

6. Global Infectious Disease Diagnostics Market, by Technology
6.1. Introduction
6.2. Immunodiagnostics
6.3. Clinical Microbiology
6.4. Polymerase Chain Reaction (PCR)
6.5. Isothermal Nucleic Acid Amplification Technology (INAAT)
6.6. DNA Sequencing and Next-Generation Sequencing (NGS)
6.7. DNA Microarray
6.8. Other Technologies

7. Global Infectious Disease Diagnostics Market, by Disease Type
7.1. Introduction
7.2. Hepatitis
7.3. Human Immunodeficiency Virus (HIV)
7.4. Hospital-Acquired Infections (HAIs)
7.5. Human Papillomavirus (HPV)
7.6. Tuberculosis (TB)
7.7. Influenza
7.8. Other Infectious Diseases

8. Global Infectious Disease Diagnostics Market, by End User
8.1. Introduction
8.2. Hospital & Clinical Laboratories
8.3. Diagnostic Reference Laboratories
8.4. Academic & Research Institutes
8.5. Other End Users

9. Global Infectious Disease Diagnostics Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.6. Middle East and Africa

10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Market Share Analysis (2019)
10.3.1. F. Hoffmann-La Roche Ltd.
10.3.2. Abbott Laboratories
10.3.3. Danaher Corporation

11. Company Profiles
11.1. Abbott Laboratories
11.1.1. Business Overview
11.1.2. Financial Overview
11.1.3. Product Portfolio
11.1.4. Strategic Development
11.1.4.1. New Product Launches and Approvals
11.1.4.2. Acquisitions
11.1.4.3. Partnerships
11.2. Danaher Corporation
11.2.1. Business Overview
11.2.2. Financial Overview
11.2.3. Product Portfolio
11.2.4. Strategic Developments
11.2.4.1. New Product/Service Launches and Approvals
11.2.4.2. Acquisitions
11.2.4.3. Partnerships, Collaborations, and Agreements
11.3. Bio-Rad Laboratories, Inc.
11.3.1. Business Overview
11.3.2. Financial Overview
11.3.3. Product Portfolio
11.3.4. Strategic Developments
11.3.4.1. New Product Launches and Approvals
11.4. Biomérieux S.A.
11.4.1. Business Overview
11.4.2. Financial Overview
11.4.3. Product Portfolio
11.4.4. Strategic Development
11.4.4.1. New Product Launches & Approvals
11.4.4.2. Acquisitions
11.5. F. Hoffmann-La Roche, Ltd.
11.5.1. Business Overview
11.5.2. Financial Overview
11.5.3. Product Portfolio
11.5.4. Strategic Development
11.5.4.1. New Product Launches & Approvals
11.6. Becton, Dickinson and Company
11.6.1. Business Overview
11.6.2. Financial Overview
11.6.3. Product Portfolio
11.6.4. Strategic Developments
11.6.4.1. New Product Launches, Enhancements, and Approvals
11.6.4.2. Acquisitions
11.6.4.2. Agreements
11.7. Diasorin s.p.a.
11.7.1. Business Overview
11.7.2. Financial Overview
11.7.3. Product Portfolio
11.7.4. Strategic Developments
11.7.4.1. New Product Launches & Approvals
11.7.4.2. Acquisitions
11.7.4.3. Collaborations
11.8. Meridian Bioscience, Inc.
11.8.1. Business Overview
11.8.2. Financial Overview
11.8.3. Product Portfolio
11.8.4. Strategic Developments
11.8.4.1. New Product Launches and Enhancements
11.8.4.2. Collaborations
11.8.4.3. Acquisitions
11.9. Quidel Corporation
11.9.1. Business Overview
11.9.2. Financial Overview
11.9.3. Product Portfolio
11.9.4. Strategic Developments
11.9.4.1. Product Approvals
11.9.4.2. Acquisitions
11.10. Thermo Fisher Scientific, Inc.
11.10.1. Business Overview
11.10.2. Financial Overview
11.10.3. Product Portfolio
11.10.4. Strategic Developments
11.10.4.1. New Product Launches and Approvals
11.10.4.2. Collaborations
11.10.4.3. Acquisitions

12. Appendix
12.1. Questionnaire
12.2. Available Customization

List of Tables

Table 1 Global Infectious Disease Diagnostics Market Drivers: Impact Analysis (2020-2027)
Table 2 COVID 19 Confirmed Cases and Deaths Across the World (2nd May 2020)
Table 3 Recent Diagnostic Tests Launched for COVID-19
Table 4 Global Infectious Disease Diagnostics Market Restraints: Impact Analysis (2020-2027)
Table 5 Clinical Applications of Infectious Disease Genomics and Proteomics
Table 6 Global Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 7 Recent Launches and Approvals in The Consumables Market
Table 8 Key Companies Offering Infectious Disease Diagnostic Consumables
Table 9 Global Infectious Disease Diagnostic Consumables Market Size, by Country/Region, 2018-2027 ($ Million)
Table 10 Key Companies Offering Infectious Disease Diagnostic Instruments
Table 11 Global Infectious Disease Diagnostic Instruments Market Size, by Country/Region, 2018-2027 ($Million)
Table 12 Key Companies Offering Infectious Disease Diagnostic Software and Services
Table 13 Global Infectious Disease Diagnostic Software & Services Market Size, by Country/Region, 2018-2027 ($ Million)
Table 14 Global Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($ Million)
Table 15 Key Companies Offering Immunodiagnostic-Based Products
Table 16 Global Immunodiagnostic-Based Infectious Disease Diagnostics Market Size, by Country/Region, 2018-2027 ($ Million)
Table 17 Global Clinical Microbiology-Based Infectious Disease Diagnostics Market Size, by Country/Region, 2018-2027 ($Million)
Table 18 Key Companies Offering PCR-Based Products
Table 19 Global PCR-Based Infectious Disease Diagnostics Market Size, by Country/Region, 2018-2027 ($Million)
Table 20 Global INAAT-Based Infectious Disease Diagnostics Market Size, by Country/Region, 2018-2027 ($ Million)
Table 21 Global DNA Sequencing and NGS-Based Infectious Disease Diagnostics Market Size, by Country/Region, 2018-2027 ($Million)
Table 22 Global DNA Microarray-Based Infectious Disease Diagnostics Market Size, by Country/Region, 2018-2027 ($Million)
Table 23 Global Infectious Disease Diagnostics Market Size for Other Technologies, by Country/Region, 2018-2027 ($Million)
Table 24 Global Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 25 Global Infectious Disease Diagnostics Market Size for Hepatitis, by Country/Region, 2018-2027 ($ Million)
Table 26 Key Players Offering HIV Diagnostic Products
Table 27 Global Infectious Disease Diagnostics Market Size for HIV, by Country/Region, 2018-2027 ($Million)
Table 28 Global Infectious Disease Diagnostics Market Size for HAIs, by Country/Region, 2018-2027 ($ Million)
Table 29 Global Infectious Disease Diagnostics Market Size for HPV, by Country/Region, 2018-2027 ($ Million)
Table 30 Global Infectious Disease Diagnostics Market Size for Tuberculosis, by Country/Region, 2018-2027 ($ Million)
Table 31 Some of the FDA-Cleared Nucleic Acid Detection-Based Tests for Influenza (2019)
Table 32 Global Infectious Disease Diagnostics Market Size for Influenza, by Country, 2018-2027 ($ Million)
Table 33 COVID 19 Confirmed Cases and Deaths Across the World (2nd May 2020)
Table 34 Diagnostic Tests for COVID-19
Table 35 Global Infectious Disease Diagnostics Market Size for Other Infectious Diseases, by Country, 2018-2027 ($ Million)
Table 36 Global Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($ Million)
Table 37 Global Infectious Disease Diagnostics Market Size for Hospital & Clinical Laboratories, by Country, 2018-2027 ($ Million)
Table 38 Global Infectious Disease Diagnostics Market Size for Diagnostic Reference Laboratories, by Country, 2017-2027 ($Million)
Table 39 Global Infectious Disease Diagnostics Market Size for Academic & Research Institutes, by Country, 2017-2027 ($Million)
Table 40 Global Infectious Disease Diagnostics Market Size for Other End Users, by Country, 2017-2027 ($Million)
Table 41 Global Infectious Disease Diagnostics Market Size, by Country/Region, 2018-2027 ($Million)
Table 42 North America: Infectious Disease Diagnostics Market Size, by Country, 2018-2027 ($Million)
Table 43 North America: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 44 North America: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 45 North America: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 46 North America: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 47 U.S.: Disease Rate and Number of New Cases (2016 & 2017)
Table 48 U.S.: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 49 U.S.: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 50 U.S.: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 51 U.S.: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 52 Canada: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 53 Canada: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 54 Canada: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 55 Canada: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 56 Europe: Infectious Disease Diagnostics Market Size, by Country, 2018-2027 ($Million)
Table 57 Europe: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 58 Europe: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 59 Europe: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 60 Europe: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 61 Germany: HIV and AIDS Estimates (2018)
Table 62 Personalized Therapies Authorized in Germany (2017)
Table 63 Germany: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 64 Germany: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 65 Germany: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 66 Germany: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 67 France: Percentage of Older People (65 Years and Above), 2010-2050
Table 68 France: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 69 France: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 70 France: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 71 France: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 72 U.K.: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 73 U.K.: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 74 U.K.: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 75 U.K.: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 76 Italy: Cancer Prevalence 2018
Table 77 Number of Cancer Cases, (2018 Vs 2040)
Table 78 Italy: Covid-19 Cases
Table 79 Italy: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 80 Italy: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 81 Italy: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 82 Italy: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 83 Spain: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 84 Spain: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 85 Spain: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 86 Spain: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 87 Hepatitis A Cases (2016 Vs.2017)
Table 88 Covid-19 Cases in European Countries
Table 89 RoE: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 90 RoE: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 91 RoE: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 92 RoE: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 93 Asia-Pacific: Infectious Disease Diagnostics Market Size, by Country, 2018-2027 ($Million)
Table 94 Asia-Pacific: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 95 Asia-Pacific: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 96 Asia-Pacific: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 97 Asia-Pacific: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 98 China: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 99 China: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 100 China: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 101 China: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 102 Japan: Percentage Geriatric Population (65 and Over)
Table 103 Japan: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 104 Japan: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 105 Japan: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 106 Japan: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 107 India: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 108 India: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 109 India: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 110 India: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 111 RoAPAC: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 112 RoAPAC: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 113 RoAPAC: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 114 RoAPAC: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 115 Latin America: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 116 Latin America: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 117 Latin America: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 118 Latin America: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 119 EDCTP Funding for Infectious Disease Diagnostics (2003-2018)
Table 120 Middle East & Africa: Infectious Disease Diagnostics Market Size, by Product & Service, 2018-2027 ($Million)
Table 121 Middle East & Africa: Infectious Disease Diagnostics Market Size, by Technology, 2018-2027 ($Million)
Table 122 Middle East & Africa: Infectious Disease Diagnostics Market Size, by Disease Type, 2018-2027 ($Million)
Table 123 Middle East & Africa: Infectious Disease Diagnostics Market Size, by End User, 2018-2027 ($Million)

List of Figures

Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Size Estimation
Figure 7 Global Infectious Disease Diagnostics Market, by Product & Service, 2020 Vs. 2027 ($Million)
Figure 8 Global Infectious Disease Diagnostics Market Size, by Technology, 2020 Vs. 2027 ($Million)
Figure 9 Global Infectious Disease Diagnostics Market Size, by Disease Type, 2020 Vs. 2027 ($Million)
Figure 10 Hospitals & Clinical Laboratories Are Expected to Dominate the Global Infectious Disease Diagnostics Market, by End User (2020-2027)
Figure 11 Infectious Disease Diagnostics Market, by Region
Figure 12 Market Dynamics
Figure 13 Global Infectious Disease Diagnostics Market Size, by Product & Service, 2020-2027 ($Million)
Figure 14 Global Infectious Disease Diagnostics Market Size, by Technology, 2020-2027 ($Million)
Figure 15 Global Infectious Disease Diagnostics Market Size, by Disease Type, 2020-2027 ($Million)
Figure 16 U.S.: Hospital-Acquired Infections
Figure 17 Tuberculosis R&D Funding (2015-2018)
Figure 18 Laboratory Confirmed Hospitalization Rate for Influenza, 2019-2020
Figure 19 Global Infectious Disease Diagnostics Market Size, by End User, 2020-2027 ($Million)
Figure 20 Tuberculosis R&D Funding (2015-2018)
Figure 21 Global Infectious Disease Diagnostics Market Size, by Geography, 2020-2027 ($Million)
Figure 22 North America: Infectious Disease Diagnostics Market Snapshot
Figure 23 U.S. Health Expenditure for Homecare Settings (2005-2017) (In $Billion)
Figure 24 Europe: Infectious Disease Diagnostics Market Snapshot
Figure 25 Germany: Infection Data, by Infection Site, 2010-2016 (%)
Figure 26 Asia-Pacific: Infectious Disease Diagnostics Market Snapshot
Figure 27 China: Geriatric Population (Million)
Figure 28 Coronavirus Outbreak in Latin America (6th May 2020)
Figure 29 Healthcare Expenditure in Latin America (2012-2016)
Figure 30 Key Growth Strategies Adopted by Leading Players, 2017-2020
Figure 31 Infectious Disease Diagnostics: Competitive Benchmarking
Figure 32 Market Share Analysis: Infectious Disease Diagnostics Industry, 2019
Figure 33 Abbott Laboratories: Financial Overview (2019)
Figure 34 Danaher Corporation: Financial Overview (2019)
Figure 35 Bio-Rad Laboratories, Inc.: Financial Overview (2019)
Figure 36 Biomérieux S.A.: Financial Overview (2018)
Figure 37 F. Hoffmann-La Roche, Ltd.: Financial Overview (2019)
Figure 38 Becton, Dickinson and Company: Financial Overview (2019)
Figure 39 Diasorin s.p.a.: Financial Overview (2018)
Figure 40 Meridian Bioscience, Inc.: Financial Overview (2019)
Figure 41 Quidel Corporation: Financial Overview (2019)
Figure 42 Thermo Fisher Scientific, Inc.: F

Download Sample

Full Name:

Name can only consist of alphabets.

Please provide your full name.

Email:

Please provide valid email address.

Please provide your email address.

Job Title:

Please provide your job title.

Comapany:

Please provide your company name.

City:

Please provide your company name.

Phone Number

Please provide valid phone number.

Please provide your phone number.

Specific Interest

Please enter minimum 10 characters.

Captcha:

Please enter Captcha.

Please enter valid Captcha.

This website is secure and we do not share your personal information with any third party. Privacy Policy

SELECT PDF LICENSE

Single User 10% Discount

$ 3757.5 ~~$ 4175.00~~ With the help of Single User License, only an individual can use our report either electronically or online. The right to use of the report should be confined only to one authorized computer. Upon buying single user license, buyer must provide the names and email ids of the authorized users of this report.

Multiple Users 15% Discount

$ 5078.75 ~~$ 5975.00~~
Multi-User license permits to access the report from five authorized computers. It does not permit you to share the report with other divisions and subsidiaries of the same company. Upon buying multi-user license, buyer must provide the names and email ids of the authorized users of this report. (Recommended)

Corporate User 20% Discount

$ 5740 ~~$ 7175.00~~ With corporate use license, the complete or part of the content of the report can be shared or made available to other persons, other divisions and subsidiaries of same company. However, reproduction or redistribution of the report is prohibited without the prior permission of Meticulous Research.

Enquire

Check Discount

Request Sample

Speak to Analyst